Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q4 Loss

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.2 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• Vireo Growth completes acquisition of C21 Investments